DE60218445D1 - Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe - Google Patents
Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffeInfo
- Publication number
- DE60218445D1 DE60218445D1 DE60218445T DE60218445T DE60218445D1 DE 60218445 D1 DE60218445 D1 DE 60218445D1 DE 60218445 T DE60218445 T DE 60218445T DE 60218445 T DE60218445 T DE 60218445T DE 60218445 D1 DE60218445 D1 DE 60218445D1
- Authority
- DE
- Germany
- Prior art keywords
- isochinoline
- chinolin
- inhibition
- raf kinase
- pyridine urea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83828501A | 2001-04-20 | 2001-04-20 | |
US838285 | 2001-04-20 | ||
PCT/US2002/012066 WO2002085857A2 (en) | 2001-04-20 | 2002-04-18 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60218445D1 true DE60218445D1 (de) | 2007-04-12 |
DE60218445T2 DE60218445T2 (de) | 2007-11-29 |
Family
ID=25276729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60218445T Expired - Lifetime DE60218445T2 (de) | 2001-04-20 | 2002-04-18 | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1379505B1 (de) |
JP (1) | JP4366936B2 (de) |
AT (1) | ATE355272T1 (de) |
CA (1) | CA2443950C (de) |
DE (1) | DE60218445T2 (de) |
ES (1) | ES2283543T3 (de) |
MX (1) | MXPA03009648A (de) |
WO (1) | WO2002085857A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
EP2426122A1 (de) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylenharnstoffderivate als Inhibitoren von RAF Kinase |
JP4613157B2 (ja) * | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
CA2516931C (en) * | 2003-02-28 | 2014-09-09 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
EP1603879A2 (de) * | 2003-02-28 | 2005-12-14 | Bayer Pharmaceuticals Corporation | Zur behandlung von krebs und anderen erkrankungen geeignete substituierte pyridinderivate |
WO2004085433A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
PT1626714E (pt) * | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
BR122016015715B8 (pt) | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
WO2005037285A1 (en) * | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
CA2548571A1 (en) * | 2003-12-10 | 2005-06-30 | Merck Patent Gmbh | Diacylhydrazine derivatives |
TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
AU2005217033A1 (en) * | 2004-02-26 | 2005-09-09 | Merck Patent Gmbh | Isoquinoline derivatives |
EP2295427A1 (de) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituierte Pyrazolyl-harnstoff-derivate zur Behandlung von Krebs |
AU2005264988B2 (en) | 2004-06-17 | 2011-09-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
JP2008517064A (ja) | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | P38mapキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成 |
GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
US20080207658A1 (en) * | 2005-02-25 | 2008-08-28 | Manley Paul W | Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors |
PL1868579T3 (pl) | 2005-03-07 | 2011-03-31 | Bayer Healthcare Llc | Kompozycja farmaceutyczna zawierająca difenylomocznik podstawiony omega-karboksyarylem do leczenia nowotworu |
DE102005010454A1 (de) | 2005-03-08 | 2006-09-21 | Robert Bosch Gmbh | Gassensor |
ES2580108T3 (es) | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Compuestos de isoquinolina |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
JP5072595B2 (ja) | 2005-08-05 | 2012-11-14 | 中外製薬株式会社 | マルチキナーゼ阻害剤 |
CA2627875A1 (en) | 2005-10-31 | 2007-05-10 | Bayer Pharmaceuticals Corporation | Combinations comprising sorafenib and interferon for the treatment of cancer |
JP2009519908A (ja) * | 2005-12-08 | 2009-05-21 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害活性を有する二環式化合物 |
US20070161617A1 (en) | 2005-12-15 | 2007-07-12 | Morgan Bradley P | Certain chemical entities, compositions and methods |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
ES2480440T3 (es) | 2005-12-21 | 2014-07-28 | Bayer Intellectual Property Gmbh | Derivados sustituidos de pirimidina útiles en el tratamiento del cáncer y de otros trastornos |
MX2008014953A (es) | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
DE102006029795A1 (de) * | 2006-06-27 | 2008-01-03 | Schebo Biotech Ag | Neue Harnstoff-Derivate und deren Verwendungen |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
JP2010514692A (ja) | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物 |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
CA2805874A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
HUE061618T2 (hu) | 2013-03-15 | 2023-07-28 | Aerie Pharmaceuticals Inc | Vegyület szemrendellenességek kezelésére |
US9638690B2 (en) | 2014-11-07 | 2017-05-02 | The University Of British Columbia | Compounds and compositions for use as alkylating agent sensors and methods of use thereof |
AU2015414743B2 (en) | 2015-11-17 | 2019-07-18 | Alcon Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
CA3035566A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
JP2020515583A (ja) | 2017-03-31 | 2020-05-28 | アエリエ ファーマシューティカルズ インコーポレイテッド | アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9302275D0 (en) * | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
AU2198999A (en) * | 1997-12-22 | 1999-07-12 | Bayer Corporation | Inhibition of raf kinase using substituted heterocyclic ureas |
NZ505843A (en) * | 1997-12-22 | 2003-06-30 | Bayer Ag | Diphenyl ureas compounds for treating cancer and raf kinase related diseases |
ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
EP1140840B1 (de) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US6699879B1 (en) * | 1999-02-12 | 2004-03-02 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
AUPR034000A0 (en) * | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
-
2002
- 2002-04-18 ES ES02725710T patent/ES2283543T3/es not_active Expired - Lifetime
- 2002-04-18 DE DE60218445T patent/DE60218445T2/de not_active Expired - Lifetime
- 2002-04-18 EP EP02725710A patent/EP1379505B1/de not_active Expired - Lifetime
- 2002-04-18 MX MXPA03009648A patent/MXPA03009648A/es active IP Right Grant
- 2002-04-18 CA CA2443950A patent/CA2443950C/en not_active Expired - Fee Related
- 2002-04-18 AT AT02725710T patent/ATE355272T1/de not_active IP Right Cessation
- 2002-04-18 JP JP2002583384A patent/JP4366936B2/ja not_active Expired - Fee Related
- 2002-04-18 WO PCT/US2002/012066 patent/WO2002085857A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE60218445T2 (de) | 2007-11-29 |
EP1379505A2 (de) | 2004-01-14 |
MXPA03009648A (es) | 2005-10-05 |
ES2283543T3 (es) | 2007-11-01 |
ATE355272T1 (de) | 2006-03-15 |
JP2005501813A (ja) | 2005-01-20 |
CA2443950C (en) | 2011-10-18 |
CA2443950A1 (en) | 2002-10-31 |
WO2002085857A3 (en) | 2003-01-16 |
WO2002085857A2 (en) | 2002-10-31 |
JP4366936B2 (ja) | 2009-11-18 |
EP1379505B1 (de) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60218445D1 (de) | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe | |
WO2002062763A3 (en) | Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas | |
ATE520663T1 (de) | Stickstoff atom enthaltenden heteroaryl- harnstoffe als inhibitoren der p38-kinase | |
ATE556713T1 (de) | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer | |
ATE529109T1 (de) | Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe | |
TW200510416A (en) | P38 inhibitors and methods of use thereof | |
ATE346600T1 (de) | Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen | |
EP1140840A4 (de) | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren | |
TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
WO2004078116A3 (en) | P38 inhibitors and methods of use thereof | |
NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
ATE448232T1 (de) | Substituierte heterozyklen | |
DE60315146D1 (de) | Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase | |
ATE529406T1 (de) | Aryl-harnstoffe als kinase inhibitoren | |
ATE408601T1 (de) | Fredericamycin-derivate | |
DE60237528D1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
NO20072804L (no) | Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer | |
DE60220290D1 (de) | Pyridinderivate als inhibitoren der raf-kinase | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
IS6925A (is) | Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns | |
ATE411984T1 (de) | Neue kondensierte n-pyrazinyl-sulfonamide und deren verwendung bei der behandlung von chemokinvermittelten krankheiten | |
SE0300457D0 (sv) | Novel compounds | |
DK1441723T3 (da) | Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension | |
NO970573L (no) | Ylidenforbindelser og deres fremstilling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: BAYER HEALTHCARE LLC, TARRYTOWN, N.Y., US |